We are live on ! Find out more
HS

HighVista Strategies Portfolio holdings

AUM $362M
1-Year Est. Return 230.96%
This Fund
S&P 500
This Quarter Est. Return
+12.73%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$362M
AUM Growth
-$26.1M
Cap. Flow
-$33.3M
Cap. Flow %
-9.19%
Top 10 Hldgs %
27.18%
Holding
180
New
35
Increased
46
Reduced
71
Closed
24

Top Buys

1
ABVX
Abivax
ABVX
+$4.86M
2
NRIX icon
Nurix Therapeutics
NRIX
+$3.76M
3
IVA
Inventiva
IVA
+$3.75M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$3.21M
5
DFTX
Definium Therapeutics
DFTX
+$3.15M

Top Sells

1
VRDN icon
Viridian Therapeutics
VRDN
+$7.08M
2
COGT icon
Cogent Biosciences
COGT
+$5.16M
3
RVMD icon
Revolution Medicines
RVMD
+$5.14M
4
CDTX
Cidara Therapeutics
CDTX
+$5.06M
5
ACLX
Arcellx
ACLX
+$4.89M

Sector Composition

1 Healthcare 66.93%
2 Technology 9.01%
3 Industrials 5.47%
4 Consumer Discretionary 2.89%
5 Financials 2.32%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
126
Zymeworks
ZYME
$1.78B
$853K 0.24%
+34,085
New +$806K
P
127
Everpure Inc
P
$23.1B
$827K 0.23%
14,009
-3,400
-20% -$230K
BBD icon
128
Banco Bradesco
BBD
$37.4B
$760K 0.21%
208,264
+18,000
+9% +$68.3K
CAAP icon
129
Corporacion America
CAAP
$4.05B
$752K 0.21%
29,745
-7,400
-20% -$201K
MELI icon
130
Mercado Libre
MELI
$92B
$752K 0.21%
435
-30
-6% -$57.9K
PVLA
131
Palvella Therapeutics
PVLA
$2.26B
$736K 0.2%
+5,903
New +$616K
IBN icon
132
ICICI Bank
IBN
$107B
$722K 0.2%
27,884
+1,600
+6% +$46.9K
NU icon
133
Nu Holdings
NU
$65.6B
$712K 0.2%
49,570
-13,000
-21% -$211K
PDD icon
134
Pinduoduo
PDD
$120B
$705K 0.19%
+6,900
New +$725K
BBOT
135
BridgeBio Oncology
BBOT
$686M
$700K 0.19%
78,187
-151,076
-66% -$1.62M
EDU icon
136
New Oriental
EDU
$7.82B
$698K 0.19%
12,317
-500
-4% -$28.6K
JANX icon
137
Janux Therapeutics
JANX
$992M
$686K 0.19%
49,383
+7,940
+19% +$109K
RLX icon
138
RLX Technology
RLX
$2.51B
$686K 0.19%
+311,700
New +$717K
HDB icon
139
HDFC Bank
HDB
$135B
$650K 0.18%
26,127
+4,000
+18% +$124K
NAMS icon
140
NewAmsterdam Pharma
NAMS
$3.7B
$642K 0.18%
20,067
-15,519
-44% -$506K
YMM icon
141
Full Truck Alliance
YMM
$9.48B
$641K 0.18%
77,191
-10,400
-12% -$98.9K
XNCR icon
142
Xencor
XNCR
$1.3B
$640K 0.18%
+53,045
New +$658K
TRVI icon
143
Trevi Therapeutics
TRVI
$2.71B
$639K 0.18%
53,525
-52,634
-50% -$589K
PFSI icon
144
PennyMac Financial
PFSI
$4.43B
$639K 0.18%
7,306
-500
-6% -$53.8K
RXO icon
145
RXO
RXO
$4.83B
$629K 0.17%
43,038
-47,900
-53% -$703K
SE icon
146
Sea Limited
SE
$63.7B
$617K 0.17%
7,450
– –
NOK icon
147
Nokia
NOK
$56.5B
$569K 0.16%
70,824
+11,300
+19% +$83K
QXO
148
QXO Inc
QXO
$14.9B
$511K 0.14%
26,320
-32,400
-55% -$741K
URGN icon
149
UroGen Pharma
URGN
$1.96B
$477K 0.13%
26,510
-1,495
-5% -$30K
KRYS icon
150
Krystal Biotech
KRYS
$10.5B
$471K 0.13%
+1,824
New +$485K
4 5
6
7 8

Similar funds

RWM
Revisor Wealth Management Akron, Ohio $362M AUM 15.97% 1-Year Est. Return
SIAG
Safeguard Investment Advisory Group Corona, California $362M AUM 20.96% 1-Year Est. Return
WI
WBI Investments Red Bank, New Jersey $362M AUM 23.75% 1-Year Est. Return
MSL
MILLINGTON SECURITIES, LLC Red Bank, New Jersey $362M AUM
BHBT
Burke & Herbert Bank & Trust Alexandria, Virginia $362M AUM 20.5% 1-Year Est. Return
CAP
Cordoba Advisory Partners New York $362M AUM
WTFG
Wood Tarver Financial Group Boise, Idaho $362M AUM 14.75% 1-Year Est. Return
RC
Reik & Co New York $363M AUM 3.03% 1-Year Est. Return

HighVista Strategies's Q1 2026 Portfolio in Review

As of Q1 2026, HighVista Strategies held 180 positions worth $362M, down 6.7% from $388M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

HighVista Strategies withdrew a net $33.3M in Q1 2026, closing 24 positions and reducing 71 holdings. Its most notable exit was Cidara Therapeutics, an estimated $5.06M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 70% a quarter earlier, followed by Technology and Industrials.

Against the trend, HighVista Strategies opened a new position in Nurix Therapeutics worth $3.51M.

  • HighVista Strategies's largest Q1 2026 buy was Nurix Therapeutics: 226,546 shares worth $3.51M.
  • HighVista Strategies added most to Abivax in Q1 2026, an estimated $4.86M increase.
  • HighVista Strategies's biggest Q1 2026 reduction was Viridian Therapeutics, cutting an estimated $7.08M.
  • HighVista Strategies fully exited Cidara Therapeutics in Q1 2026, selling an estimated $5.06M.
  • HighVista Strategies's ten largest holdings make up 27% of its $362M portfolio in Q1 2026.
  • HighVista Strategies opened 35 new positions and closed 24 in Q1 2026.
  • HighVista Strategies's portfolio value fell 6.7% quarter-over-quarter to $362M.

Based on HighVista Strategies's 13F filing for Q1 2026, filed 15 May 2026.